Novartis drug cut death risk by 35 percent in gene mutation breast cancer

An experimental cancer drug that Novartis hopes will raise the profile of its oncology portfolio cut the risk of death or disease progression by more than a third in breast cancer patients with a hard-to-target gene mutation.
Original Article